Generation Bio Co..
GBIO.US | Research and experimental development on natural sciences and engineering
Generation Bio Co. is a biotechnology company focused on developing genetic medicines for inherited diseases. The company's proprietary platform is designed to deliver durable, redosable gene therapies by leveraging its closed-ended DNA (ceDNA) technology. This technology aims to overcome limitation...Show More
Better Health for All
40
Generation Bio Co. is a biotechnology company whose entire business is devoted to developing genetic medicines for rare and prevalent diseases, aiming to significantly improve lives.
1
Its R&D efforts, such as achieving approximately 98% knockdown of B2M protein in human T cells in studies, demonstrate a focus on exceptional health benefits.
2
The company has no revenue from products with negative health impacts, as it is in the preclinical development stage.
3
All of the company's R&D expenses are dedicated to health improvement, with $61.3 million for the year ended December 31, 2024, and $15.4 million for Q1 2025.
4
The company plans to submit an investigational new drug (IND) application in the second half of 2026, indicating a commitment to entering clinical trials, which are subject to ethical standards.
5
Fair Money & Economic Opportunity
0
No evidence available to assess Generation Bio Co. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess Generation Bio Co. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Generation Bio Co. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Generation Bio Co. on Honest & Fair Business.
Kind to Animals
0
No evidence available to assess Generation Bio Co. on Kind to Animals.
No War, No Weapons
0
No specific, concrete evidence was found in the provided articles to assess Generation Bio Co. against any of the 'No War, No Weapons' KPIs. The articles discuss general export controls on dual-use biotechnology products
1
and an ESG risk rating for the company
2
, but do not provide data on its revenue from arms contracts, R&D investment in dual-use technologies, sales to embargoed regimes, peacebuilding investments, or any other specific metrics related to military or conflict involvement. , which discusses a conflict minerals policy
3
, is for 'Gen Digital Inc.'
4
and not for 'GBIO.US (Generation Bio Co.)'
5
, and is therefore not applicable.
Planet-Friendly Business
0
No specific quantitative data or relevant information regarding GBIO.US's planet-friendly business practices, environmental performance, or climate initiatives could be found in the provided articles.
1
All articles explicitly state that their content is generic or placeholder text and contains no data relevant to the company or the ethical value being assessed.
2
Respect for Cultures & Communities
0
The company has no reported cultural appropriation incidents.
1
It provides a formal grievance mechanism for interested parties, including community stakeholders, to report concerns to the board of directors or a committee via written communication, allowing for anonymous or confidential submissions.
2
The company's operations do not involve Free, Prior, and Informed Consent (FPIC) processes.
3
Safe & Smart Tech
0
Generation Bio's privacy policy indicates that users can request the deletion of their data.
1
No other specific evidence regarding the company's performance against the Safe & Smart Tech value was found in the provided articles.
Zero Waste & Sustainable Products
-10
The company has set waste reduction targets, aiming to reduce waste generation by 50% by 2025 compared to 2015 (per million euro turnover) and to recycle at least 85% of waste.
1
Hazardous waste is disposed of by licensed companies in line with the strictest standards.
2
The company has not incurred any specific regulatory actions, violations, fines, or compliance issues related to waste disposal.
3